FOLFIRINOX Versus Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines
| Autor: | Carlos Fernandez-del Castillo, Andrew S. Liss, Sebastian K.S. Begg, Keith D. Lillemoe, Oliver Schilling, Ulrich F. Wellner, David J Birnbaum, Mari Mino-Kenudson, Andrew L. Warshaw, Jeffrey W. Clark |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chemotherapy endocrine system diseases business.industry FOLFIRINOX medicine.medical_treatment General Medicine medicine.disease digestive system diseases Gemcitabine Oxaliplatin Irinotecan chemistry.chemical_compound Paclitaxel chemistry Fluorouracil Pancreatic cancer Internal medicine medicine business medicine.drug |
| Zdroj: | Anticancer Research. 40:3659-3667 |
| ISSN: | 1791-7530 0250-7005 |
| DOI: | 10.21873/anticanres.14355 |
| Popis: | Background/aim FOLFIRINOX [fluorouracil (5-FU), irinotecan, oxaliplatin] and gemcitabine plus nab-paclitaxel are standard treatments for patients with pancreatic ductal adenocarcinoma (PDAC). Despite efficacy rates of less than 32%, evidence is lacking to guide the use of one drug over the other. Herein, we compared the sensitivity of patient-derived PDAC cell lines to each of these regimens. Materials and methods Changes in the growth of 19 low-passage patient-derived PDAC cell lines were evaluated in response to treatment with FOLFIRINOX and gemcitabine plus paclitaxel (Gem-Pac). Results Six cell lines exhibited optimal sensitivity (high EMax and low GI50) to FOLFIRINOX and three cell lines exhibited optimal sensitivity to Gem-Pac. Several cell lines that were optimally sensitive to one drug regimen exhibited very poor response to the other. Conclusion Further characterization of cancer cells exhibiting preferential sensitivity to each of these regimens may allow the identification of biomarkers to guide the selection of appropriate chemotherapy for a given patient. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|